Investigation of Biofilm Formation and its Association with the Molecular and Clinical Characteristics of Methicillin-resistant Staphylococcus aureus  by Cha, Jeong-Ok et al.
Osong Public Health Res Perspect 2013 4(5), 225e232
http://dx.doi.org/10.1016/j.phrp.2013.09.001
pISSN 2210-9099 eISSN 2233-6052- ORIGINAL ARTICLE -Investigation of Biofilm Formation and its
Association with the Molecular and Clinical
Characteristics of Methicillin-resistant
Staphylococcus aureusJeong-Ok Cha a, Jae Il Yoo a, Jung Sik Yoo a, Hae-Sun Chung b,
Sun-Hee Park c, Hwa Su Kim a, Yeong Seon Lee a, Gyung Tae Chung a,*
aDivision of Antimicrobial Resistance, Korea National Institute of Health, Osong, Korea.
bDepartment of Laboratory Medicine, Ewha Womans University School of Medicine,
Seoul, Korea.
cDepartment of Internal Medicine, Daejeon St. Mary’s Hospital, Daejeon, Korea.Received: July 23, 2013
Revised: August 5,
2013
Accepted: September
2, 2013
KEYWORDS:
biofilm,
blood stream infection,
clinical features,
methicillin-resistant
Staphylococcus aureus*Corresponding author.
E-mail: gtchung@nih.go.kr
This is an Open Access article distribu
creativecommons.org/licenses/by-nc/3.
medium, provided the original work is p
Copyright ª 2013 Korea Centers for DiseAbstract
Objectives: To investigate the biofilm-forming related factors against MRSA
bloodstream isolates and evaluates their clinical features and treatment out-
comes by biofilm production.
Methods: We collected 126 consecutive methicillin-resistant Staphylococcus
aureus (MRSA) causing blood stream infections (BSIs) at 10 tertiary hospitals from
2007 to 2009. We investigated biofilm-forming ability using a microtiter plate
assay, and molecular characteristics including multilocus sequence typing,
staphylococcal cassette chromosome mec and accessory gene regulator types.
We compared the clinical characteristics and outcomes of patients infected with
biofilm-forming and non-biofilm-forming MRSA isolates.
Results: Of the 126 samples, 86 (68.3%), including 5 strong level (OD570  1.0)
and 81 weak level (0.2  OD570 < 1.0), had biofilm-forming capacity. Detection of
fibronectinbinding protein in biofilm-forming strains was significantly higher than
biofilm non-forming ones (p Z 0.001) and three enterotoxin genes (sec-seg-sei)
islands had a high frequency regardless of biofilm production. However, biofilm-
forming strains were more likely to be multidrug resistant (three or more non-b-
lactam antibiotics) than biofilm non-forming ones [79.2% vs. 59.2%, p Z 0.015,
odds ratio (OR) 2.629, 95% confidence interval (CI) 1.92e5.81]. Clinical features
of patients with BSIs caused by biofilm-forming MRSA strains were more likely to
be hospital onset [77.9% vs. 60.0%, p Z 0.024, OR 2.434, 95% CI 1.11e5.33) and
more frequently occurred in patients with use of invasive devices [85.7% vs.ted under the terms of the Creative Commons Attribution Non-Commercial License (http://
0) which permits unrestricted non-commercial use, distribution, and reproduction in any
roperly cited.
ase Control and Prevention. Published by Elsevier Korea LLC. All rights reserved.
226 J.-O. Cha, et al61.2%, pZ 0.002, OR 3.879, 95% CI 1.61e8.97]. The other clinical features were
compared with the clinical outcomes of the two groups and were not significant
(p > 0.05).
Conclusion: Biofilm-forming MRSA strains showed higher frequency of fnbB gene
than biofilm non-forming ones and more incidence rates on particular genotypes.
And, their patient’s features were not significantly different between two groups
in this study, except for several clinical factors.1. Introduction
Biofilms are defined as communities of bacteria
encased in a self-synthesized extracellular polymeric
matrix that attaches to a biotic or abiotic surface and
biofilm-forming staphylococci including Staphylococcus
aureus and Staphylococcus epidermidis in gram-positive
bacteria have been as one of the major cause of chronic
polymer-associated infection [1e3]. Infections involving
biofilm-forming bacteria are extremely difficult to erad-
icate because biofilms impair antibiotic penetration and
prevent normal immune responses [4e6]. It has been
known that methicillin-resistant S. aureus (MRSA) cause
many device-related infections and other chronic in-
fections grow in biofilms or on these devices. Some
studies have shown that it is very difficult to treat biofilm-
forming staphylococcal infections with antibiotics [7e9].
Moreover, MRSA is the most common cause of noso-
comial infections in intensive care units in Korea. Addi-
tionally, representative healthcare-associated MRSA
strains have progressed to community-associated in-
fections, as has been demonstrated in Korea [10]. How-
ever, the prevalence of community-associated MRSA
strains in healthcare settings is increasing. Here, we
studied the biofilm-forming ability of MRSA blood
stream infections (BSIs) and analyzed the relationship
between molecular characteristics and their clinical fea-
tures for MRSA biofilm formers.2. Materials and Methods
2.1. Bacterial strains and case definition
We collected MRSA isolates from consecutive un-
related patients in intensive care unit with MRSA BSI at
10 tertiary hospitals from 2007 to 2009. MRSA BSI was
considered to be present if one or more blood cultures
had positive results, and if clinical signs and course were
consistent with MRSA infection. Further case defini-
tions were defined, as previously described [11].
2.2. Identification and antimicrobial
susceptibility testing
Identification and antimicrobial susceptibility testing
were done using Vitek II (bioMe´rieux, Craponne,
France) or MicroScan Pos Combo Panel Type 6
(Siemens, Munich, Germany) and confirmed by PCR forthe presence of mecA gene. We used the following S.
aureus strains: ATCC25923, ATCC29213, ATCC43300
(mecA, positive control) from the American Type Cul-
ture Collection (Manassas, VA, USA). In addition,
antimicrobial susceptibility testing were performed with
the disc diffusion method, if needed, according to the
Clinical and Laboratory Standards Institute guidelines.
S. aureus ATCC 29213 were used as quality control
strains for MICs.
2.3. Biofilm formation assay
The biofilm formation assay in microtiter wells was
performed as previously described [12]. First, overnight
cultures were diluted 1:100 in brain heart infusion broth
(Becton Dickinson and Co., Franklin Lakes, NJ, USA)
supplemented with 1% glucose. Cell suspensions
(200 mL) were transferred to individual wells of a flat-
bottom 96-well polystyrene microtiter plate (Nunclon;
Nunc, Roskilde, Denmark). After incubation at 35 C
for 48 hours, detached cells were gently rinsed three
times with sterile water, and the bacteria that attached to
the surface were stained with crystal violet, rewashed,
and destained with 1 mL of ethanol-acetone (95:5, vol/
vol). A total of 200 mL of the mixed solution was
transferred to a 96-well microtiter plate for spectro-
photometric analysis at optical density (OD) 570 nm.
The absorbance was recorded by Micro-ELISA autor-
eader (Titertek Multiscan Plus; Labsystems, Helsinki,
Finland). Each assay was performed in triplicate and the
mean OD570 value of tested wells was applied to
biofilm-forming ability. Uninoculated medium was used
to determine background. The biofilm formation were
divided into three categories in this study, the strains
with OD570 < 0.2, 0.2  OD570 < 1.0, and OD570  1.0
were defined as biofilm non-formers, biofilm formers of
week level, and strong level, based on the ODs in brain
heart infusion broth with and without two supplements.
S. aureus SA113 (ATCC35556) and Staphylococcus
epidermidis RP62A (ATCC35984), well-characterized
biofilm-forming strains, were purchased from Amer-
ican Type Culture Collection for use as positive
controls.
2.4. Molecular typing
SCCmec types were determined by using a multiplex
PCR strategy according to the method described by
Oliveira and de Lancastre [13]. The agr type (1e4) was
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locus sequence typing was carried out according to
protocol previously described [15,16]. Data were
analyzed by comparing the database at the multilocus
sequence typing website (http://saureus.mlst.net), and
the sequence type (ST) for each strain was determined.
2.5. Detection of virulence genes
All 126 strains were analyzed by PCR assay as pre-
viously described [12,17]. These included nine staph-
yloccocal enterotoxin genes (sea, seb, sec, sed, see, seg,
seh, sei, sej ), three exfoliative toxin genes (eta, etb,
etd ), six adhesin genes (icaA, icaD, cna, atl, fnbA,
fnbB), two surface-associated genes (cap5HK, cap8HK ),
and two staphylococcal regulators (sarA, arlRS ).
2.6. Clinical features and outcome
Medical, laboratory, and pharmacy records were
reviewed. Data from patients infected with biofilm-
forming and non-forming MRSA isolates were
compared. The data collected included age, sex, primary
site, and onset of infection. In addition, clinical outcome
was assessed for all assessable cases according to biofilm-
forming capacity. The outcome measures used were
crude mortality, MRSA-related death, and eradication of
MRSA. Healthcare-associated risk factors included the
following: presence of invasive devices (central venous
catheter, urinary catheter, and other indwelling devices),
prior use of antibiotics, residence in long-term care fa-
cility, prior hospitalization, prior surgery, receipt of he-
modialysis, and prior MRSA colonization.
2.7. Statistical analysis
Data analysis was performed using Statistical Pack-
age for the Social Sciences (SPSS) Software version
10.0 (SPSS Inc., Chicago, IL, USA) and MedCalc Sta-
tistical Software version 10.0.1.0 (MedCalc Software
Inc., Mariakerke, Belgium). Statistical significance was
assessed via the Pearson c2 test or the Fisher exact test
for categorical variables and the Student t test or the
ManneWhitney U test for continuous variables. Logis-
tic regression analysis was used for multivariate anal-
ysis. Variables that achieved a probability of <0.1 in
univariate analyses were considered for inclusion in
logistic regression models.3. Results
3.1. Antimicrobial susceptibility and biofilm
formation
A total of 126 MRSA isolates from blood cultures
were analyzed; 86 strains (68.3%) had biofilm-forming
ability with five strong and 81 weak level and the other
strains (40/126, 31.7%) did not form biofilms (Figure 1).
All isolates were resistant to oxacillin and penicillin.
Biofilm-forming isolates were less frequently resistantto oxacillin and penicillin (14.0% vs. 42.5%;
p Z 0.005), and they were more likely to be multidrug
resistant (three or more non-b lactam antibiotics) than
biofilm nonforming ones (85.0% vs. 57.5%; p < 0.001;
Table 1).
3.2. Comparison of genotypic characteristics
The genetic characteristics of 126 MRSA strains
were differed between biofilm-forming and nonforming
isolates (Table 2). Most biofilm-forming (55 isolates;
64.0%) and biofilm-nonforming (20 isolates; 50.0%)
isolates were of agr group II, with no difference in the
distribution of the agr group. The most common
SCCmec type was II in both biofilm-forming and non-
forming isolates, and the next most frequent type was
SCCmec type IV (p Z 0.055). Biofilm-forming isolates
were more likely to contain ST5 (69.8% vs. 52.5%;
p Z 0.060), ST239 (8.1% vs. 2.5%; p Z 0.434) and
significantly less likely to contain ST72 (18.6% vs.
42.5%; p Z 0.005) than biofilm nonforming isolates.
3.3. Determination of virulence-associated genes
Table 3 presents the distribution of virulence-
associated genes (adhesin-encoding, toxin-encoding,
surface-associated, and gene regulators). With a range
over 90%, most of the isolates had similar distribution of
adhesion genes (icaA, icaD, cna, atl, and fnbA), toxin
genes (SEs, hla, and hlb), and staphylococcal regulators
(sarA and arlRS ) between biofilm-forming and non-
forming isolates and both isolates showed low frequency
in detection of eta, etb, etd, PVL, and cap8HK. The
biofilm-forming isolates were significantly more detec-
ted in distribution of fnbB than biofilm-nonforming
isolates (74.4% vs. 45.0%; p Z 0.001; odds ratio
3.556; 95% confidence interval 1.615e7.827).
3.4. Clinical features of patients by biofilm-
forming ability
Epidemiological and clinical data were available for
126 patients and were included in the analysis of factors
associated with biofilm formation. Patient characteristics
are shown in Table 4. Biofilm-forming isolates were
more frequently detected in nosocomial infection
(77.9%) than biofilm-nonforming isolates (60%).
Among 86 nosocomial infection, biofilm-forming iso-
lates were involved in 67 cases (77.9%), which was
higher than community onset cases (22.1%). There were
no significant differences in sites of infection. CRI and
primary infection were two most common origins of
MRSA infection regardless of biofilm-forming ability.
As shown in Table 4, there were no significant differ-
ences between clinical outcomes of biofilm-forming and
nonforming cases for crude mortality and MRSA-related
death, in univariate analysis shown in Table 5, signifi-
cant risk factors associated with healthcare-associated
biofilm-forming isolates were the presence of invasive
devices (central venous catheter, urinary catheter, and
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Figure 1. Biofilm-forming capacity of 126 methicillin-resistant Staphylococcus aureus (MRSA) isolates by tissue culture plate
(TCP) assay.
228 J.-O. Cha, et alother indwelling devices) and prior hospitalization
(p < 0.05). Odds ratios (95% confidence interval) for the
variable selected in multivariate analysis were: presence
of invasive devices, 3.87 (1.60e8.96); and prior hospi-
talization, 0.40 (0.18e0.88).4. Discussion
The ability to form biofilm is a trait that is closely
associated with bacterial persistence and virulence, and
many persistent and chronic bacterial infections are
now believed to be linked to the formation of biofilms
[18]. In this study, we analyzed the presence of various
virulence genes and adherent proteins against MRSAsTable 1. Comparison of antimicrobial susceptibilities between
Antibiotic resistance p
Biofilm formers (86) OX-P
OX-P-CLI
OX-P-TET
OX-P-CIP-CLI
OX-P-CLI-TET
OX-P-CIP-TET
OX-P-CIP-CLI-SXT
OX-P-CIP-CLI-TET
OX-P-CIP-CLI-TET
Biofilm non-formers (40) OX-P
OX-P-CIP
OX-P-TET
OX-P-CIP-CLI
OX-P-CIP-CLI-TET
OX-P-CIP-CLI-TET
CIP Z ciprofloxacin; CLI Z clindamycin; OX Z oxacillin; P Z penicillin;causing BSI. The high proportion (about 80e95%) of
MRSA isolates in our study could make no significant
difference for virulence genes according to biofilm-
forming capacity, except for fnbB gene. We found the
fnbB gene was to be more frequent among biofilm-
producing MRSA strains of ST5 (34/86 isolates) and
biofilm non-producing MRSA strains of ST72 (16/40
isolates) respectively (p Z 0.005)(data not shown).
ST5 strains have been known as frequent genotype in
hospital and ST72 in community environment, espe-
cially in Asia [11, 19, 20]. In our results, MRSAs of
ST5 and ST72 genotypes showed a frequency of fnbB
for either biofilm formers or non-formers. This means
that the presence of fnbB gene may be correlated with
the biofilm-forming ability and MRSA trait from abiofilm-forming and nonforming isolates
rofiles No. of isolates %
12/86 13.9
4/86 4.7
1/86 1.2
7/86 8.1
1/86 1.2
1/86 1.2
1/86 1.2
57/86 66.2
-SXT 1/86 1.2
17/40 42.5
1/40 2.5
1/40 2.5
3/40 7.5
17/40 42.5
-SXT 1/40 2.5
SXT Z trimethoprim-sulfamethoxazole; TET Z tetracycline.
Table 2. Genotypic distribution between biofilm-forming and nonforming isolates
Characteristic
No. (%) of MRSA isolates
p*
Biofilm formers
(n Z 86)
Biofilm non-formers
(n Z 40)
agr group
I 25 (29.1) 18 (45.0) 0.357
II 55 (64.0) 20 (50.0)
III 3 (3.5) 1 (2.5)
SCCmec type
I 0 (0.0) 0 (0.0) 0.055
II 60 (69.8) 20 (50.0)
III 6 (7.0) 1 (2.5)
IV 18 (20.9) 18 (45.0)
MLST
ST1 2 (2.3) 1 (2.5)
ST5 60 (69.8) 21 (52.5) 0.060
ST8 1 (1.2) 0 (0.0)
ST72 16 (18.6) 17 (42.5) 0.005
ST239 7 (8.1) 1 (2.5) 0.434
*The p values comparing the values for the two groups were determined using a two-sample test for binomial proportions. MLSTZ multilocus sequence
typing; MRSA Z methicillin-resistant Staphylococcus aureus.
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with a previous study [21], suggesting that FnbB-
mediated biofilm development is a common MRSA
trait from clonal complex (CC) 8, CC22, and CC45
lineages. However, studies of the relationship of spe-
cific STs and biofilm formation require further
investigation.Table 3. Distribution of virulence-associated genes by function
Functional category
No
Positive, n Z 86
Adhesin-encoding genes
icaA 83 (96.5)
icaD 86 (100)
cna 80 (93.0)
atl 86 (100)
fnbA 83 (96.5)
fnbB 64 (74.4)
Toxin-encoding genes
SEs 86 (100)
eta, etb, etd 1 (1.2)
tst 78 (90.7)
PVL 2 (2.3)
hla 83 (96.5)
hlb 86 (100)
Surface-associated genes
cap5HK 75 (87.2)
cap8HK 9 (10.5)
Staphylococcal regulators
sarA 86 (100)
arlRS 80 (93.0)
The percentages refer to the percentage of patients within each Staphylococcu
*The p values comparing the values for the two groups were determined using
exact test; all p values shown in this table (referring to a comparison of values
with a false discovery rate of < 20%.Epidemiologically biofilm-forming MRSA infection
was highly associated with nosocomial infection in this
study. Hospital environments may be more suitable for
biofilm formation. Various healthcare-associated risk
factors are suggested to affect biofilm formation pref-
erable environments to a greater or lesser extent. Our
results showed that significant risk factors were theal category
. of isolates by biofilm formation (%);
Negative, n Z 40 p*
38 (95.0) 0.652
40 (100)
36 (90.0) 0.724
40 (100)
39 (97.5) 1.000
18 (45.0) 0.001
40 (100)
0 (0.0) 1.000
34 (39.5) 0.370
0 (0.0) 1.000
38 (95.0) 0.652
39 (97.5) 0.317
35 (87.5) 0.964
3 (7.5) 0.751
40 (100)
39 (97.5) 0.430
s aureus subset with the indicated virulence gene.
a two-sided Fisher’s exact test (p < 0.05). As determined by the Fisher
for biofilm-forming and non-forming isolates) are statistically significant
Table 4. Summary of clinical characteristics
Characteristics
Biofilm formers
n (%)
Bioflim non-formers
n (%) p OR (CI95)
Age, years 0.203 0.985 (0.964e1.008)
Mean  SD 63.8  12.5 56.7  14.7
Median (range) 69 (1e98) 65 (1e80)
Male:female 56:30 26:14 0.990
MRSA isolates
Onset of infection
Nosocomial 67 (77.9) 24 (60.0) 0.024 2.434 (1.111e5.331)
Community onset 19 (22.1) 16 (40.0)
Site of infection
Endocarditis 2 (2.3) 0 (0) 0.255
Lung infection 7 (8.1) 5 (12.5) 0.407
SSTI/Bone 8 (9.3) 3 (7.5) 0.857
CRI 31 (36.0) 21 (52.5) 0.466
Other sites 3 (3.5) 0 (0) 0.281
Primary 33 (38.4) 14 (35.0) 0.629
Clinical outcome
Crude mortality 29 (37.7) 16 (40.0) 0.423
MRSA-related death 16 (18.6) 6 (15.0) 0.203
Eradication of MRSA 0.824
Success 56 (72.7) 26 (65.0)
Failure 19 (22.1) 10 (25.0)
CI95 Z 95% confidence interval; CRI Z catheter-related infection; MRSA Z methicillin-resistant Staphylococcus aureus; OR Z odds ratio;
SD Z standard deviation; SSTI, staphylococcal skin and tissue infection.
230 J.-O. Cha, et alpresence of invasive devices and prior hospitalization.
Even though not significant statistically, proportions of
patients with prior antibiotic use and prior MRSA
colonization were higher in biofilm-forming isolates
than nonforming isolates. However, among the com-
munity onset cases, nearly half of the isolates revealed
biofilm-forming activities. This suggests that biofilm
formation may be troublesome in community-associated
MRSA as well as healthcare-associated MRSA.
It is widely known that biofilm might play a role in
the pathogenesis of device-associated MRSA infections.
Particularly, the presence of biofilms on intravascular
catheters and their role in catheter-related BSI (CRBSI)
is well accepted [22]. We defined CRBSI according to
the Infectious Diseases Society of America guidelines
[23,24], but the diagnosis of CRBSI remains a majorTable 5. Healthcare-associated risk factors associated with biofi
Healthcare-associated risk
factors Biofilm formers (%) Biofilm
Presence of invasive
device
85.7
Prior antibiotic use 71.6
Residence in LTCF 12.5
Prior hospitalization 60.2
Prior surgery 36.4
Receipt of hemodialysis 26.1
Prior MRSA colonization 33.8
LTCF Z long-term care facility.challenge. Although proven CRBSI cases in patients
with biofilm-forming isolates were lower than primary
BSI in this study, biofilm-formation was significantly
associated with the presence of invasive devices, which
suggests that invasive devices may be the hidden focus
of MRSA BSI. However, this causal relation was not
proven and further studies would be necessary to
investigate this possibility.
Biofilm infections are important clinically because
bacteria in biofilms exhibit recalcitrance to antimicro-
bial compounds and persistence in spite of sustained
host defenses [25]. Biofilm infection represents a
reservoir of dissemination of bacterial infection to other
sites in the human body [26]. During infection, attach-
ment is a crucial part of the colonization on host tissues
or on indwelling medical devices, whereas detachmentlm-forming capacity
non-formers (%) p
Odds ratio (95%
confidence interval)
61.2 0.002 3.87 (1.60e8.96)
62.5 0.535 1.37 (0.49e3.89)
10.0 0.704 1.30 (0.33e5.12)
40.0 0.024 0.40 (0.18e0.88)
17.5 0.121 0.47 (0.17e1.22)
30.0 0.278 1.65 (0.66e4.09)
15.0 0.295 0.61 (0.24e1.54)
Biofilm formation in Staphylococcus aureus 231is a prerequisite for the dissemination of an infection.
Fux et al [20] reported that the detachment of multi-
cellular clumps may explain the high rate of symptom-
atic metastatic infections seen with S. aureus. They also
revealed that nonattached aggregates of bacteria retain
the antibiotic resistance seen in biofilms. Collectively,
biofilm formation can lead to intractable infection and
worse outcome.
However, significant differences in outcomes be-
tween biofilm-forming and nonforming cases were not
observed. There are some possible explanations. First,
we targeted MRSA isolates that already exhibited a high
level of resistance in a significant portion, which may
reduce the effects of enhanced antimicrobial resistance
due to biofilms. Clinical outcomes are very complex and
comprehensive products of various factors including not
only bacterial factors but also host factors. Therefore, it
is difficult to demonstrate the independent effects of
biofilm. In particular, we included patients in intensive
care units with MRSA BSI at tertiary hospitals, who
generally have very severe status and showed high
mortality. By contrast, evaluation of the duration of
bacteremia and symptoms would produce different re-
sults, as previous studies revealed the association of
biofilms and persistent infection [1,25,27], but the in-
formation was not submitted.
In summary, most MRSA isolates related to BSI
produced biofilms and their genotypic characteristics
have a tendency to having prevalence in some STs and
specific genes. Therefore, the patients having biofilm-
forming MRSAs seem to be associated with prior use of
a medical device and prior hospitalization. These mo-
lecular and epidemiological analyses for biofilm-
producing MRSAs could be given as basic information
for patients who cannot be treated, and may be helpful in
determining the possibility of biofilm-related S. aureus
infections.Acknowledgments
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